Stay updated with breaking news from Affinity Biosensors. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Affinity Biosensors, a Santa Barbara-based healthcare diagnostics company, announced April 3 that its flagship LifeScale AST system has received FDA clearance. The company said that the FDA’s approval was a milestone that clears the way for healthcare professionals to begin using an important tool for managing bacteremia by providing antibiotic susceptibility test (AST) results with
Affinity Biosensors of Santa Barbara announced Wednesday that the diagnostic company's LifeScale AST system has received clearance from the U.S. Food and Drug Administration.
/PRNewswire/ -- Affinity Biosensors, a leading innovator in the field of healthcare diagnostics, announces that its groundbreaking LifeScale AST system has...
/PRNewswire/ -- The study, titled PERFORMANCE EVALUATION OF THE LIFESCALE AST RAPID AUTOMATED ANTIMICROBIAL SUSCEPTIBILITY SYSTEM, assessed the performance of...
Affinity Biosensors announces that University of Louisville Hospital completed its evaluation of the LifeScaleAST rapid antibiotic susceptibility ...